Trusted Second Opinion Partner - Cromwell Hospital

Second Opinion Press
oncology-facility
test-solutions-for-cancer

Who We Are?

Datar Cancer Genetics is a leading multinational molecular oncology facility, started with a clear vision:

To transform cancer care through precision oncology. By leveraging advanced molecular science, we aim to make non-invasive blood tests accessible for improved cancer management, especially for those facing advanced cancer.

Our easy-to-access tests enable patients to take swift action against cancer.

At Datar Cancer Genetics, we are dedicated to supporting you every step of the way with precision and care.

Our Mission

At Datar Cancer Genetics, we are driven by a passion to transform cancer care through relentless innovation, groundbreaking research, and a steadfast commitment to improving patient outcomes.

We believe that personalised cancer treatment is the future, and we are at the forefront of this shift, leveraging molecular oncology to develop non-invasive and blood-based tests that empower clinicians with precise and actionable insights. By embracing the complexities of each patient's cancer and focusing on individualised care, we aim to pioneer advanced solutions that make a meaningful difference in patients' lives, bringing hope and effective treatments to patients globally.

Our products are CE-marked and therefore meet the EU health, safety, and environmental requirements, which ensure patient safety. 

journey-milestones

Our Journey

Since our foundation in India in 2013, we have been dedicated to advancing non-invasive cancer detection and personalised therapies.

2013-2017

Began pioneering research on Circulating Tumour Cells (CTCs) to create non-invasive methods for early cancer detection and treatment guidance.

2018-2020

Expanded our reach to Germany and established a laboratory in the UK to bring our innovative solutions closer to patients worldwide.

2021

Reached key milestones, including FDA approval for TriNetra™- Breast, a blood test to screen for breast cancer, and UK recognition for TruBlood™-Prostate, a non-invasive test for prostate cancer diagnosis.

Corporate Team

Mr Rajan Datar

MR. RAJAN DATAR

Promoter, Datar Cancer Genetics
[BSc, LLB]

Ms Swati Deshpande

Ms. SWATI DESHPANDE

Senior Director
[BSc, LLB, Healthcare Management, (ISB)]

Dr Vineet Datta

Dr. VINEET DATTA

Senior Director
[MD FRCP (GLASG) MCEM, FRSPH CMQ/ASG]

Dr Darshana Patil

DR. DARSHANA PATIL

Senior Director
[MD (Pathology), MMO (CNIO)]

Dr Stefan Schuster

DR. STEFAN SCHUSTER

Managing Director, Europe
[PhD (Medicinal Chemistry)]

Ms Sneha Datar

Ms. SNEHA DATAR

Director
[LLB]

Steve Parr

Steve Parr

Sr. Director - Early Detection
[NHS & RWD]

Medical Affairs

Dr Ashwini Ghaisas

DR. ASHWINI GHAISAS

Director, Applications
[MBBS, MRCOG, D OBS]

Dr Atreyee Saha

DR. ATREYEE SAHA

Laboratory Director
[UK]

Dr Navin Shrivastava

DR. NAVIN SHRIVASTAVA

Laboratory Director
[PhD (Biochemistry)]

Advisors

Dr Tim Crook

Dr. TIM CROOK

Medical Oncologist
[BSc, PhD, MBBS, MRCP, FRCP]

Dr Andy Gaya

Dr. ANDY GAYA

Medical Oncologist
[MD, MRCP, FRCR]

Prof Dr Kefah Mokbel1

Prof. Dr. KEFAH MOKBEL

Breast Cancer Surgeon
[MS, FRCS]

Prof Dr Nick Plowman1

Prof. Dr. NICK PLOWMAN

Medical Oncologist
[MA, MD, FRCP, FRCR]

Our Test Portfolio

To fulfil our vision, we have developed a range of non-invasive blood tests that provide personalised insights to guide cancer treatment, helping doctors make informed decisions tailored to each patient. Our approved products include:

Trucheck™ Intelli

Trucheck™ Intelli is a non-invasive blood test designed to detect cancer early by identifying cancer cells in your bloodstream, even before symptoms appear.

KNOW MORE

Trublood™

Trublood™ is a no-risk alternative to traditional biopsies, offering a safe, accurate, and cost-effective method for detecting solid tumours (that occur in organ systems of the body) and brain tumours without any invasive procedures.

KNOW MORE

Exacta™

Exacta™ is a comprehensive genomic test designed to identify key genetic alterations and pathways driving the cancer, enabling us to understand which treatments might work best against it.

KNOW MORE

Celldx™

Celldx™ is a comprehensive genomic test to identify actionable therapy options based on guideline-recommended genes for tumours that occur in solid organ systems of the body.

KNOW MORE

Chemoscale™

Chemoscale™ is a non-invasive test that analyses tumour cells to evaluate how a chemotherapy drug may work or reveal potential resistance. This helps guide the selection of the most effective treatment.

KNOW MORE

Cancertrack™

Effective cancer management requires a proactive treatment approach that stays ahead of tumour growth. Traditional methods, like scans, can take over three months to indicate if a treatment is working for you.

KNOW MORE